|
USA-MS-DIAMONDHEAD Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- Pathophysiology of Stroke - Strokeforum
A stroke occurs when the blood flow to an area of the brain is interrupted, resulting in some degree of permanent neurological damage The two major categories of stroke are ischaemic (lack of blood and hence oxygen to an area of the brain) and haemorrhagic (bleeding from a burst or leaking blood vessel in the brain) stroke
- Classification of stroke | Strokeforum
Classification of stroke 1 Stroke is a heterogeneous disease with more than 150 known causes Strokes can broadly be divided into: Ischaemic - restricted or interrupted blood and therefore oxygen supply to an area of the brain; Haemorrhagic - bleeding into an area of the brain, due to rupture of a blood vessel or abnormal vascular structure in
- Understanding AIS - Stroke facts | Strokeforum
Stroke versus TIA Stroke was defined by the World Health Organization in the 1970s, as being a "neurological deficit of cerebrovascular cause that persists beyond 24 hours or is interrupted by death within 24 hours" The arbitrarily chosen timeframe of 24 hours divided strokes from transient ischaemic attacks (TIAs) 2
- Symptoms and Mimics - Strokeforum
Acute ischaemic stroke patients require time-critical reperfusion treatments, so rapid identification of stroke symptoms and a quick reaction time are critical to initiate prompt intervention The FAST test is popular for identifying acute stroke symptoms where FAST stands for F ace drooping, A rm weakness, S peech difficulty, T ime to call emergency 1,2
- Risk factors of STEMI - stemi-care. com
It has been found that an increased risk of coronary heart disease or stroke exists if there is a first- degree blood relative with the same condition Having a sibling with a history of CVD is associated with a 45% increased risk of cardiovascular disease 11 Summary In terms of attributable deaths, globally, CV risk factors are: 12
- Home | SYNJARDY - JARDIANCE
EMPA-REG OUTCOME ® trial: primary composite outcome was 3-point MACE, composed of CV death from CV causes, nonfatal MI, or nonfatal stroke, in patients with T2D and established CV disease (N=7020), on top of standard of care; as analysed in the pooled JARDIANCE ® group vs the placebo group The 14% RRR in 3-point MACE (HR=0 86; 95% CI: 0 74, 0 99) was driven by a reduction in the risk of CV
- Protection+ │JARDIANCE | JARDIANCE
The primary composite outcome in the EMPA-REG OUTCOME ® trial was 3-point MACE, composed of death from CV causes, nonfatal MI, or nonfatal stroke, as analyzed in the pooled JARDIANCE ® group vs the placebo group Patients were adults with insufficiently controlled T2D and CAD, PAD, or a history of MI or stroke The 14% RRR in 3-point MACE (HR=0 86; 95% CI: 0 74, 0 99; p<0 001 for
- Protect Patients Early with JARDIANCE®
The primary composite outcome in the EMPA-REG OUTCOME ® trial was 3-point MACE, composed of death from CV causes, nonfatal MI, or nonfatal stroke, as analysed in the pooled JARDIANCE ® group vs the placebo group Patients were adults with insufficiently controlled T2D and CAD, PAD, or a history of MI or stroke The 14% RRR in 3-point MACE (HR=0 86; 95% CI: 0 74, 0 99;
- JARDIANCE® Benefits | Discover the JARDIANCE® Story
‡ The primary composite outcome in the EMPA-REG OUTCOME® trial was 3-point MACE, composed of death from CV causes, nonfatal MI, or nonfatal stroke, as analyzed in the pooled JARDIANCE ® group vs the placebo group Patients were adults with insufficiently controlled T2D and CAD, PAD, or a history of MI or stroke The 14% RRR in 3-point MACE (HR=0 86; 95% CI: 0 74, 0 99; p
- Dosing - JARDIANCE
The primary composite outcome in the EMPA-REG OUTCOME ® trial was 3-point MACE, composed of death from CV causes, nonfatal MI, or nonfatal stroke, as analyzed in the pooled JARDIANCE ® group vs the placebo group Patients were adults with insufficiently controlled T2D and CAD, PAD, or a history of MI or stroke The 14% RRR in 3-point MACE (HR=0 86; 95% CI: 0 74, 0 99; p<0 001 for
|
|